Complaints and Serious Adverse Event Reporting Workflow

21 CFR Part 111 Subpart O  |  21 CFR 111.560, 111.570  |  FD&C Act Section 761
21 CFR 111.553  ·  111.560  ·  111.570
FD&C Act Section 761  ·  21 USC 379aa-1
Serious adverse events must be reported to FDA
within 15 business days of receipt
Phase 1 - Receive and Record
Phase 2 - Review and Investigate
Phase 3 - Report Serious Adverse Events
Phase 4 - Respond, Record, and Improve
Decision point
GMPify Procedural Map Series
📞

Complaints and Serious Adverse Event Reporting - Receiving, Investigating, and Reporting What Comes Back From the Market

Dietary supplement manufacturers must follow written procedures to review every product complaint, investigate those that suggest a specification failure or other Part 111 problem, and keep a record of each complaint. Separately, the responsible person named on the label must report serious adverse events to FDA on the MedWatch form within 15 business days, with a copy of the label, and must send new medical information within the same time. This map details the pathway from receipt through review, investigation, reporting, response, and record keeping.

21 CFR Part 111 Subpart O  ·  111.560  ·  111.570  ·  FD&C Act Section 761
21 CFR 111.553 to 111.570
FD&C Act Section 761
MedWatch Report

Product Complaint

Any complaint received about a dietary supplement. Each is reviewed, and those suggesting a possible failure are investigated.

Basis: Subpart O

Serious Adverse Event

An adverse event with death, a life-threatening experience, hospitalization, lasting disability, birth defect, or need for medical or surgical intervention.

Basis: FD&C Act Section 761

Responsible Person

The manufacturer, packer, or distributor whose name is on the label. This person submits the serious adverse event report to FDA.

Basis: Named on the label

Quality Control

Quality control decides whether to investigate a complaint and approves the findings and follow-up actions.

Basis: 111.560(b)
Phase 1
Receive and Record
1Provide a contact for adverse event reports on the label
The label carries the address or phone number through which the responsible person receives adverse event reports.
FD&C Act Section 761
↓
2Follow written procedures for complaints
Written procedures established and followed for the review, investigation, and recording of product complaints.
21 CFR 111.553
↓
3Receive and record each complaint at the time
Product name and description, batch or lot number if known, date received, complainant details if available, and the nature of the complaint.
21 CFR 111.570(b)(2)
↓
4A qualified person reviews every complaint
Each complaint reviewed to decide whether it suggests a possible specification failure or other Part 111 problem.
21 CFR 111.560(a)
Phase 2
Review and Investigate
Is it a possible serious adverse event?
YES → Start the 15 business day clock NO → Continue the complaint review
↓
5Quality control decides whether to investigate
QC decides whether an investigation is needed and approves that decision.
21 CFR 111.560(b)
↓
6Investigate a possible specification failure
Investigate complaints suggesting the supplement may not meet specifications or other Part 111 requirements, including those that could lead to illness or injury.
21 CFR 111.560(a)
↓
7Extend the review to all relevant batches and records
Review, investigation, and decisions cover every relevant batch and its records, not only the complained-of unit.
21 CFR 111.560(c)
Phase 3
Report Serious Adverse Events
8Confirm the event is serious
Check the event against the statutory definition of a serious adverse event, using reasonable medical judgment for the intervention criterion.
FD&C Act Section 761
↓
9Submit the MedWatch report within 15 business days
Report sent to FDA on the MedWatch form with a copy of the product label, within 15 business days of receipt.
FD&C Act Section 761
↓
10Send new medical information within 15 business days
New medical information received within one year of the initial report is submitted within 15 business days of receipt.
FD&C Act Section 761
Phase 4
Respond, Record, and Improve
11Quality control approves findings and follow-up
QC reviews and approves the investigation findings and the follow-up actions taken.
21 CFR 111.560(b)
↓
12Reply to the complainant and record the reply
Any reply sent to the complainant is recorded with the complaint, along with the findings and follow-up actions.
21 CFR 111.570(b)(2)
↓
13Retain records and use complaint trends to improve
Complaint records kept under Subpart P, adverse event records kept for 6 years, and trends used to drive corrective action.
21 CFR 111.570; Section 761
Report Types (Overview)

Product Complaint

Reviewed by a qualified person. Investigated when it suggests a possible specification failure or other Part 111 problem.

21 CFR 111.560

Serious Adverse Event

Reported to FDA with the label copy within 15 business days of receipt.

FD&C Act Section 761

Other Adverse Events

Not submitted under Section 761, but records of adverse event reports received are retained for 6 years.

FD&C Act Section 761

Serious Adverse Event Criteria (Overview)

Death or life-threatening event The event results in death or a life-threatening experience.
Hospitalization The event results in inpatient hospitalization.
Lasting harm The event results in a persistent or significant disability or incapacity, or a congenital anomaly or birth defect.
Intervention needed Based on reasonable medical judgment, the event requires medical or surgical intervention to prevent one of the outcomes above.

Key Outputs (Overview)

Complaint record A written record of each complaint with the required details, made at the time.
Investigation record Findings and follow-up actions, approved by quality control, covering all relevant batches.
MedWatch submission Report with label copy, plus any follow-up medical information, sent on time.
Retained records Complaint records under Subpart P and adverse event records kept for 6 years.

Complaint and Adverse Event Quality Elements

Label Contact Information Consumers can reach the responsible person through the address or phone number on the label.
Single Intake Process Every channel, including calls, email, and social media, feeds the same log.
Qualified Reviewer A qualified person reviews each complaint and recognizes possible failures and adverse events.
QC Investigation Authority Quality control decides on investigation and approves findings and follow-up.
Batch Linkage Complaints are linked to the batch, so all relevant batches and records can be reviewed.
Deadline Tracking The 15 business day clock is tracked from receipt, with a named owner.
Contemporaneous Documentation Each task is documented at the time it is performed, with the required complaint details.
Trend Review Complaint and adverse event trends are reviewed and drive corrective action.

Never do this

Treat a complaint as a customer service matter only. Wait for confirmation of cause before reporting a possible serious adverse event. Investigate only the complained-of unit and ignore other batches. Leave a complaint without a written record of the reply and follow-up.

Complaint vs adverse event

A product complaint is any complaint about the product and is handled under Part 111 Subpart O. A serious adverse event is a health outcome meeting the statutory definition and is reported to FDA under Section 761. One report can be both, and then both processes apply.

When the 15 days start

The 15 business day deadline runs from receipt of the report through the address or phone number on the label. The report does not wait for the investigation or for proof the product caused the event, and sending it is not an admission of causation.

Key regulations

21 CFR 111.553 - written procedures. 111.560 - review and investigation of complaints. 111.570 - complaint records. FD&C Act Section 761 (21 USC 379aa-1) - serious adverse event reporting and records.